Frozen-thawed embryo transfer Medical Services in China

Frozen-thawed embryo transfer (FET) is not a disease but a core assisted reproductive technology (ART) procedure used in reproductive medicine to achieve pregnancy following in vitro fertilization (IVF). In FET, previously cryopreserved embryos—typically vitrified at the blastocyst stage—are carefully thawed and transferred into a prepared endometrial cavity during a natural or hormonally controlled cycle. Unlike fresh embryo transfer, FET decouples ovarian stimulation and embryo transfer, allowing for optimal endometrial receptivity assessment, avoidance of ovarian hyperstimulation syndrome (OHSS) risks, and improved synchronization between embryo developmental stage and uterine environment. Pathophysiologically, FET success hinges on three interdependent factors: embryo viability post-thaw (influenced by cryopreservation technique, embryo quality, and laboratory expertise), endometrial receptivity (modulated by hormonal priming, immune tolerance, and molecular biomarkers such as integrins and HOXA10), and procedural precision (including catheter placement, uterine contractility management, and minimization of trauma). Epidemiologically, FET accounts for over 60% of all IVF cycles in high-volume fertility centers across China and North America, with cumulative live birth rates per initiated FET cycle ranging from 45–60% in women under 35, declining to 25–35% in those aged 40–42. Key risk factors affecting outcomes include maternal age (>37 years), diminished ovarian reserve (AMH <1.1 ng/mL), recurrent implantation failure (≥3 prior failed transfers), endometriosis-associated inflammation, chronic endometritis, suboptimal endometrial thickness (<7 mm), and subclinical thyroid dysfunction. While FET itself is minimally invasive and carries low procedural morbidity, the broader fertility journey imposes substantial psychosocial burden: patients frequently report elevated anxiety, depression, marital strain, financial stress, and occupational disruption. The cyclical nature of monitoring, hormone injections, and repeated negative pregnancy tests contributes to emotional exhaustion and reduced health-related quality of life (HRQoL), particularly when multiple FET attempts are required. Importantly, FET offers distinct advantages over fresh transfer—including higher implantation and live birth rates in certain populations (e.g., PCOS, high responders), lower preterm birth and low birth weight incidence, and greater flexibility in timing—making it a first-line strategy in modern ART protocols. However, its efficacy remains highly dependent on integrated clinical, embryological, and endometrial diagnostics, underscoring the need for individualized, multidisciplinary care in reproductive medicine departments.

Frozen-thawed embryo transfer (FET) is a cornerstone procedure in modern assisted reproductive technology (ART), widely employed in reproductive medicine departments to optimize pregnancy outcomes while minimizing risks associated with fresh embryo transfer cycles. FET involves the cryopreservation of high-quality embryos following ovarian stimulation and oocyte retrieval, followed by their controlled thawing and subsequent transfer into a hormonally prepared endometrium during a subsequent menstrual cycle. This strategy decouples ovarian stimulation from embryo implantation, allowing for better endometrial receptivity assessment, improved synchronization between embryo developmental stage and uterine milieu, and reduced exposure to supraphysiological hormone levels—particularly elevated progesterone and estradiol—that may impair endometrial function.

Conservative treatment in FET primarily refers to non-invasive, cycle management strategies that prioritize natural or minimally stimulated endometrial preparation. In natural-cycle FET (NC-FET), ovulation is monitored via serial transvaginal ultrasound and serum luteinizing hormone (LH) and progesterone assays; embryo transfer is timed precisely 2–5 days post-LH surge or after confirmed ovulation. Modified natural-cycle FET incorporates low-dose hCG or GnRH agonist trigger to ensure predictable ovulation timing. These approaches avoid exogenous steroid administration entirely, preserving physiological endocrine dynamics and reducing medication burden, cost, and potential side effects such as bloating, mood fluctuations, or thromboembolic risk. NC-FET is especially suitable for women with regular ovulatory cycles and adequate endometrial thickness (>7 mm) under spontaneous hormonal conditions. However, it requires rigorous monitoring and carries a higher risk of cycle cancellation due to premature luteinization or anovulation.

Medication-based protocols constitute the most common FET regimens. Hormone replacement therapy (HRT)-FET utilizes oral, transdermal, or vaginal estradiol to induce endometrial proliferation over 10–14 days, followed by the addition of micronized progesterone (intramuscular, vaginal gel, or oral micronized formulations) to initiate secretory transformation. Endometrial thickness and pattern are assessed via ultrasound prior to progesterone initiation; optimal criteria include ≥8 mm trilaminar endometrium. Luteal phase support continues until pregnancy testing and, if positive, typically through the first 8–10 weeks of gestation to sustain early placental development. Adjunctive medications may include low-dose aspirin (for suspected chronic endometritis or thrombophilia), intravenous immunoglobulin (IVIG) or corticosteroids (in recurrent implantation failure with immune dysregulation), and antibiotics (if endometrial fluid or chronic endometritis is identified on hysteroscopy or endometrial biopsy). All pharmacologic interventions are individualized based on prior ART response, endometrial receptivity array (ERA) results, thrombophilia screening, and immune profiling.

Surgical treatment is not inherent to FET but plays a critical supportive role in optimizing endometrial receptivity. Hysteroscopy remains the gold standard for diagnosing and managing intrauterine pathology—including polyps, submucosal fibroids, intrauterine adhesions (Asherman syndrome), and chronic endometritis—that significantly reduce implantation rates. Resection of endometrial polyps >1 cm or any symptomatic lesion prior to FET improves live birth rates by up to 25%. Similarly, hysteroscopic adhesiolysis restores normal cavity architecture and vascularization, while targeted antibiotic therapy guided by endometrial culture and sensitivity testing eradicates persistent microbial colonization (e.g., *Chlamydia trachomatis*, *Mycoplasma* spp.). In select cases, endometrial scratching—performed in the luteal phase preceding FET—may modulate local immune and inflammatory responses, though recent meta-analyses show modest and inconsistent benefit. Surgical interventions are always performed in the cycle prior to FET to allow adequate endometrial healing and re-epithelialization.

China offers distinct advantages in FET delivery, rooted in its integrated, high-volume reproductive medicine infrastructure. Over 500 certified ART centers operate nationwide, many affiliated with tier-3 hospitals offering multidisciplinary care—including reproductive endocrinology, reproductive immunology, molecular genetics, and reproductive surgery—under one roof. Chinese centers utilize state-of-the-art vitrification platforms (e.g., Cryotop, Kitazato) achieving >95% embryo survival rates, supported by stringent laboratory accreditation (ISO 15189, CAP-equivalent standards). The integration of artificial intelligence–assisted time-lapse imaging for embryo selection and non-invasive PGT-A using spent embryo culture medium enhances predictive accuracy without biopsy-related risks. Moreover, China’s national ART registry enables robust outcome benchmarking and continuous quality improvement. Cost-effectiveness is notable: comprehensive FET cycles—including genetic testing, endometrial receptivity assessment, and surgical correction—cost approximately 30–50% less than comparable services in North America or Western Europe, without compromising clinical efficacy. Regulatory oversight by the National Health Commission ensures standardized protocols, mandatory embryologist certification, and strict adherence to ethical guidelines regarding embryo storage duration and disposition.

Recovery following FET is generally rapid and outpatient-based. Patients are advised to resume normal daily activities within 24 hours, avoiding vigorous exercise, heavy lifting (>10 kg), hot tubs, saunas, and sexual intercourse until pregnancy test confirmation. Mild cramping or spotting is common and does not indicate failure. Progesterone supplementation must be continued exactly as prescribed; abrupt discontinuation may precipitate luteal phase collapse. Nutritional guidance emphasizes balanced macronutrient intake, adequate hydration, and avoidance of alcohol, tobacco, and excessive caffeine (<200 mg/day). Psychological support is integral: stress reduction techniques—including mindfulness-based cognitive therapy (MBCT), acupuncture (evidence-supported for anxiety modulation), and peer-led support groups—are routinely offered. A quantitative serum β-hCG test is scheduled 12–14 days post-transfer; if positive, serial β-hCG measurements and transvaginal ultrasound at 5–6 weeks confirm viability and rule out ectopic pregnancy. For negative outcomes, comprehensive cycle review—including endometrial histopathology, embryo ploidy status, and immune markers—is conducted before planning the next attempt. Long-term follow-up includes obstetric surveillance for pregnancy complications (e.g., preeclampsia, preterm birth), given the slightly elevated risk in ART-conceived pregnancies, and counseling on perinatal mental health and lactation support.